Appointment of Iain Menneer

RNS Number : 0303J
Animalcare Group PLC
24 June 2011
 



Animalcare Group plc

 

Appointment of Iain Menneer to the Board

 

Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, announces the appointment of Dr Iain Menneer to the Board as Director of Marketing.  The appointment will take effect on 1 July 2011.

 

In December 2003, Iain Menneer joined Animalcare Ltd and has worked in marketing and business development roles, notably working on the new product development pipeline bringing such products as Benazecare, Buprecare, Enrocare and Anivac through to commercialisation. Iain has been Head of Marketing since July 2009 and Director of Marketing for Animalcare Group plc since June 2011.

 

Prior to this, Iain took a position in the Research and Innovation Office at the University of York working with academics to commercialise their research via licensing or spin-out companies.  Iain had previously graduated with a degree and PhD in chemistry from the University of Newcastle and worked in the brewing industry for 6 years; initially in research at an independent brewing consultancy and then in new product and technical development roles.

 

Stephen Wildridge, CEO of Animalcare Group plc, commented: "We are very pleased to announce the appointment of Iain to the Board.  Iain has already had a significant input into the development of the Animalcare business generally and new product developments pipeline in particular and we look forward to now having his contribution at Board level."

 

For further information:

 

Animalcare Group plc

 

Stephen Wildridge (Chief Executive Officer)

Tel: 01904 487 601

 

 

Brewin Dolphin (NOMAD)

 

Neil Baldwin

Tel: 0845 213 4726

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

Additional Information

 

Iain David Menneer, aged 41, holds 6,818 shares in the Company and other than as set out below there is no further information to be disclosed under schedule 2(g) and Rule 17 of the AIM Rules in respect of his appointment as a Director of the Company.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAZMGZVVFFGMZM
UK 100